Home > Press Room > Events > CCIT: Launching & Funding Biotech University Start-Ups
  • Print
  • Send to email


CCIT: Launching & Funding Biotech University Start-Ups

Location: CCIT, 675 US Highway One, North Brunswick, New Jersey 08902

Featuring Leaders of Biotech Academic Spin-Offs in New Jersey

Thursday, June 15, 2017
5:00 pm - 7:00 pm

Biotech leaders/CCIT graduates will tell their story and provide guidance and recommendations on launching and funding their biotech academic spin-off.

Register now and join us at the CCIT Incubator, located at the Technology Centre of New Jersey, a 75 acre life sciences research park in the heart of N.J.'s Research Corridor, for networking and guidance from:

Christian Kopfli, CEO, Chromocell - Chromocell is a spin-off from Rockefeller University.
Marc Burel, President & COO, Orthobond - Orthobond is a spin-off from Princeton University.
Michael Johnson, CEO, Visikol - Visikol is a spin-off from Rutgers University.

The panel will showcase biotech leaders on their respective paths to success, including insights into their strategy and decisions faced along the way to their companies becoming spinning out from a university.  


Commercialization Center for Innovative Technologies (CCIT)
675 US Highway One, North Brunswick, New Jersey 08902

NJEDA’s CCIT Life Sciences Incubator has partnered with Rutgers University to offer discounted space for academic spin-off companies.  For eligible academic spin-offs, office space is available for as little as $333/month.  Discounted lab space for academic spin-off companies is available at similar savings.

The CCIT life sciences incubator is located in a 75 acre research park owned by NJEDA.  CCIT is almost 50K sf with 27 wet labs and access to offices, conference rooms, biotech training events, mentoring and a great biotech eco-system.   The larger park itself is home to Chromocell, Allergan, Merial and Orthobond.  For more information, contact Program Manager, Lenzie Harcum at lharcum@njeda.com.   


Featured Speakers:


Christian Kopfli, Esq.
Chromocell, Chief Executive Officer  

Currently employing over 125, Christian co-founded Chromocell in 2002, serving initially as General Counsel before becoming Chief Executive Officer in 2005. Prior to joining Chromocell, he was an Associate at Davis Polk & Wardwell, working in its New York City, Tokyo and Frankfurt offices.  He received a doctoral degree in law (magna cum laude) from the University of Zurich in 2000 and earned his LL.M. from Columbia Law School in New York City in 1998. Christian is a Board Member of BioNJ and admitted to the Bar in New York and Switzerland.


Marc Burel
Orthobond, President and Chief Operating Officer

Marc is the President and Chief Operating Officer of Orthobond, Inc. He has also served the company as CEO and Vice President of Business Development since 2008.  He has executed Orthobond’s corporate strategy by bringing on world class business partners which have significantly impacted the growth of Orthobond. Since 2009, he has lead several successful fund raising initiatives, has expanded the team to 11, including 9 PhD scientists, and has moved the Company to its new state-of-the-art facility.


Michael Johnson, PhD

Visikol, CEO & Cofounder

Viskiol is a biotech company that “allows scientists to visualize tissues in 3-D as opposed to the traditional 2-D slices.”  Johnson, who was recently named to the Forbes “30 Under 30” list for science, started working on Visikol while he was working on a doctorate in applied microbiology at Rutgers University. Working with an advisory team of Dr. Jim Simon and Dr. Adolfina Koroch, Visikol® was originally born in the plant biology labs at Rutgers University as a safe and easy-to-use clearing agent for plant biology research. The technology has now expanded into a platform that is used for a wide-range of applications from cancer biology to better understanding human fetal development.


This event is hosted in partnership with:

BioNJ-Logo_2C_CMYK.jpg      NJTECHCIRCUITCOLOR.jpg     Rutgers.png